Inventiva jumps 25% after mid-stage data for NASH candidate
JuSun
Inventiva (NASDAQ:IVA) added ~25% on Wednesday after the French biotech announced positive data from an investigator-led Phase 2 trial for its lead candidate lanifibranor targeted at patients with liver disease nonalcoholic steatohepatitis (NASH).
Dr. Kenneth Cusi from the University of Florida ran the study on patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D).
The placebo-controlled trial designed to evaluate the effects of lanifibranor at 800mg/daily doses reached the main goal leading to a 44% decline in Intra Hepatic Triglycerides (IHTG) after 24 weeks of therapy.
In comparison, the placebo arm indicated a 12% decline in IHTG levels, Inventiva (IVA) said, adding that the results were in line with findings from its Phase IIb NATIVE trial, which showed a statistically significant reduction in steatosis for lanifibranor in NAFLD.
Additional data indicates that more patients on lanifibranor achieved over 30% liver triglyceride reduction and NAFLD resolution at week 24 compared to those on placebo with statistical significance.
The company said that the study drug was well tolerated with no safety concerns over the period. Lanifibranor is currently undergoing a pivotal Phase 3 clinical trial called NATiV3 for NASH patients.